117 related articles for article (PubMed ID: 38365149)
21. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
[TBL] [Abstract][Full Text] [Related]
22. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
23. Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.
Tang Q; Li X; Chen Y; Long S; Yu Y; Sheng H; Wang S; Han L; Wu W
Mol Carcinog; 2022 Apr; 61(4):417-432. PubMed ID: 35040191
[TBL] [Abstract][Full Text] [Related]
24. Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma.
Li X; Yu Q; Zhao R; Guo X; Liu C; Zhang K; Zhang W; Liu J; Yu J; Wang S; Hao Q; Li W; Zhang W; Li M; Zhang Y; Zhang C; Gao Y
Front Oncol; 2022; 12():898156. PubMed ID: 35814401
[TBL] [Abstract][Full Text] [Related]
25. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
26. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
27. miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression.
Chen X; Tan W; Li W; Li W; Zhu S; Zhong J; Shang C; Chen Y
J Cancer; 2019; 10(12):2745-2753. PubMed ID: 31258782
[No Abstract] [Full Text] [Related]
28. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Zhao X; Tian C; Puszyk WM; Ogunwobi OO; Cao M; Wang T; Cabrera R; Nelson DR; Liu C
Lab Invest; 2013 Jan; 93(1):8-19. PubMed ID: 23108376
[TBL] [Abstract][Full Text] [Related]
29. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.
Kanazawa T; Morisaki K; Suzuki S; Takashima Y
Mol Pharm; 2014 May; 11(5):1471-8. PubMed ID: 24708261
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Zan Y; Dai Z; Liang L; Deng Y; Dong L
Drug Deliv; 2019 Dec; 26(1):1080-1091. PubMed ID: 31735093
[TBL] [Abstract][Full Text] [Related]
31. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
32. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
33. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
34. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
35. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
[TBL] [Abstract][Full Text] [Related]
36. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Azumi J; Tsubota T; Sakabe T; Shiota G
Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
[TBL] [Abstract][Full Text] [Related]
37. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
38. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
39. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
40. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Sun T; Mao W; Peng H; Wang Q; Jiao L
Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
